Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1
- PMID: 39715971
- DOI: 10.1007/s12010-024-05103-1
Overexpression of miR-328-3p Inhibits Epithelial-Mesenchymal Transition in Prostate Cancer by Downregulating PFN1
Abstract
MicroRNA (miR)-328-3p is believed to have anti-tumor impacts in various human cancers. However, its role in prostate cancer (PCa) is uncertain. In this research, miR-328-3p expression in PCa was reduced. Meanwhile, it was discovered that miR-328-3p directly targeted profilin-1 (PFN1) 3'-untranslated region to negatively modulate PFN1. Elevating miR-328-3p or reducing PFN1 suppressed cell growth, migration, and invasion, and epithelial-mesenchymal transition; overexpression of miR-328-3p or inhibition of PFN1 delayed tumor growth in vivo. Further studies found that PCa patients with advanced T stage or high Gleason score had significantly lower miR-328-3p compared to PCa patients with early stage or low score. In addition, PCa patients with high miR-328-3p had a better prognosis than those with low miR-328-3p. Briefly, this study highlights the clinical and biological role of miR-328-3p as a tumor suppressor miRNA in PCa and explores the downstream mechanisms of miR-328-3p.
Keywords: Cell proliferation; MicroRNA-328-3p; Modulation; Prostate cancer.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: The present study was approved by the Ethics Committee of Wuxi Traditional Chinese Medicine Hospital (approval number: WX2011695T316) and written informed consent was provided by all patients prior to the study start. All procedures were performed in accordance with the ethical standards of the Institutional Review Board and The Declaration of Helsinki, and its later amendments or comparable ethical standards. All animal experiments were complied with the ARRIVE guidelines and performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The experiments were approved by the Ethics Committee of Wuxi Traditional Chinese Medicine Hospital (approval number: WX2011983T530). Consent to Participate: Written informed consent was obtained from each subject. Consent for Publication: Written informed consent for publication was obtained from all participants. Competing Interests: The authors declare no competing interests.
Similar articles
-
Elevated miR-221-3p inhibits epithelial-mesenchymal transition and biochemical recurrence of prostate cancer via targeting KPNA2: an evidence-based and knowledge-guided strategy.BMC Cancer. 2025 Jan 8;25(1):34. doi: 10.1186/s12885-025-13444-1. BMC Cancer. 2025. PMID: 39780096 Free PMC article.
-
Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.PLoS One. 2013;8(3):e58929. doi: 10.1371/journal.pone.0058929. Epub 2013 Mar 12. PLoS One. 2013. PMID: 23554959 Free PMC article.
-
Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.Mol Cancer. 2017 Jul 10;16(1):117. doi: 10.1186/s12943-017-0688-6. Mol Cancer. 2017. PMID: 28693582 Free PMC article.
-
Profilin 1, negatively regulated by microRNA-19a-3p, serves as a tumor suppressor in human hepatocellular carcinoma.Pathol Res Pract. 2019 Mar;215(3):499-505. doi: 10.1016/j.prp.2018.12.012. Epub 2018 Dec 12. Pathol Res Pract. 2019. PMID: 30638858
-
microRNA-802 inhibits epithelial-mesenchymal transition through targeting flotillin-2 in human prostate cancer.Biosci Rep. 2017 Mar 15;37(2):BSR20160521. doi: 10.1042/BSR20160521. Print 2017 Apr 30. Biosci Rep. 2017. Retraction in: Biosci Rep. 2023 Mar 31;43(3):BSR-2016-0521_RET. doi: 10.1042/BSR-2016-0521_RET. PMID: 28188157 Free PMC article. Retracted.
Cited by
-
Effect of Fold-Promoting Mutation and Signal Peptide Screening on Recombinant Glucan 1,4-Alpha-maltohydrolase Secretion in Pichia pastoris.Appl Biochem Biotechnol. 2025 Apr;197(4):2579-2597. doi: 10.1007/s12010-024-05145-5. Epub 2025 Jan 8. Appl Biochem Biotechnol. 2025. PMID: 39777640
References
-
- Nevedomskaya, E., Baumgart, S. J., & Haendler, B. (2018). Recent advances in prostate cancer treatment and drug discovery. International Journal of Molecular Sciences, 19(5). https://doi.org/10.3390/ijms19051359
-
- Sumanasuriya, S., & De Bono, J. (2018). Treatment of advanced prostate cancer-A review of current therapies and future promise. Cold Spring Harbor Perspectives in Medicine, 8(6). https://doi.org/10.1101/cshperspect.a030635
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous